Eric Widera, MD

@ewidera.bsky.social

Professor of #Medicine @UCSF focused on #Geriatrics, #Hospice, #Palliative care, and #meded. Co-creator of https://eprognosis.ucsf.edu. Podcasts at http://geripal.org 🇺🇦 Publications: https://profiles.ucsf.edu/eric.widera

How Pharma exploites a regulatory loophole allowing approval of high-priced, minimally modified drugs based on limited data. This example is on an Alzheimer’s drug called Zunveyl which is basically galantamine without safety data in the population that it’s indicated in. ebm.bmj.com/content/earl...

FDA approval of benzgalantamine exposes flaws in the 505(b)(2) pathway for innovations on existing drugs

When the US Food and Drug Administration (FDA) approved benzgalantamine (Zunveyl) in July 2024 for Alzheimer’s disease, it was hailed by its manufacturer as a ‘major breakthrough’.1 In reality, benzga...

ebm.bmj.com

“…the growing enthusiasm for biomarkers risks obscuring a fundamental truth: biomarkers only reflect disease pathology. They cannot assess cognition or illuminate the functional changes that transform memory concerns into meaningful impairment.” #alz jamanetwork.com/journals/jam...

Importance of Function for Alzheimer Diagnosis and Management

This Viewpoint offers a reminder, amid new laboratory testing for Alzheimer disease, of the primary care practitioner’s important role in functional assessment of activities of daily living.

jamanetwork.com